SK Bioscience Unveils Strategic Initiative for Post-Pandemic Era
===============
#23f3e1d2 ver:0.05
In the ever-evolving biopharmaceutical industry, companies are facing economic challenges and making strategic decisions to ensure long-term success. Layoffs and restructuring initiatives have become common in 2023 as companies prioritize certain programs, reduce expenses, and focus on near-term value.
IGM Biosciences, Travere, Pfizer, and AbCellera are among the companies that have announced staff cuts. These measures are aimed at reallocating resources and optimizing investments. Other companies, including Novocure, Generation Bio, and Lyell, are restructuring to extend their cash runways and realign their investments.
Organizational changes and workforce reductions are also being made by Gilead Sciences, Sangamo Therapeutics, and Galapagos. These companies are seeking to optimize reso...
#newstr #SkBioscience #Pharmaceutical #SkGroup #Postpandemic #Vaccine #R&d #Glocalization